Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders
- PMID: 21886592
- PMCID: PMC3137184
- DOI: 10.2174/157015911795017047
Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders
Abstract
Autism spectrum disorders (ASDs) are heterogenous neurodevelopmental disorders characterized by impairment in social, communication skills and stereotype behaviors. While autism may be uniquely human, there are behavioral characteristics in ASDs that can be mimicked using animal models. We used the BTBR T+tf/J mice that have been shown to exhibit autism-like behavioral phenotypes to 1). Evaluate cannabinoid-induced behavioral changes using forced swim test (FST) and spontaneous wheel running (SWR) activity and 2). Determine the behavioral and neurochemical changes after the administration of MDMA (20 mg/kg), methamphetamine (10 mg/kg) or MPTP (20 mg/kg). We found that the BTBR mice exhibited an enhanced basal spontaneous locomotor behavior in the SWR test and a reduced depressogenic profile. These responses appeared to be enhanced by the prototypic cannabinoid, Δ(9)-THC. MDMA and MPTP at the doses used did not modify SWR behavior in the BTBR mice whereas MPTP reduced SWR activity in the control CB57BL/6J mice. In the hippocampus, striatum and frontal cortex, the levels of DA and 5-HT and their metabolites were differentially altered in the BTBR and C57BL/6J mice. Our data provides a basis for further studies in evaluating the role of the cannabinoid and monoaminergic systems in the etiology of ASDs.
Keywords: Autism; BTBR T+tf/J mice.; Behavior; Cannabinoid; MPTP; Monoamines; Psychostimulants; Δ9-THC.
Figures



Similar articles
-
The Role of Nicotinic Receptors in the Attenuation of Autism-Related Behaviors in a Murine BTBR T + tf/J Autistic Model.Autism Res. 2020 Aug;13(8):1311-1334. doi: 10.1002/aur.2342. Epub 2020 Jul 21. Autism Res. 2020. PMID: 32691528
-
Histamine H3 receptor antagonism modulates autism-like hyperactivity but not repetitive behaviors in BTBR T+Itpr3tf/J inbred mice.Pharmacol Biochem Behav. 2022 Jan;212:173304. doi: 10.1016/j.pbb.2021.173304. Epub 2021 Nov 29. Pharmacol Biochem Behav. 2022. PMID: 34856309
-
Inbred strain preference in the BTBR T+ Itpr3tf /J mouse model of autism spectrum disorder: Does the stranger mouse matter in social approach?Autism Res. 2019 Aug;12(8):1184-1191. doi: 10.1002/aur.2158. Epub 2019 Jun 17. Autism Res. 2019. PMID: 31206258
-
Reduced social interaction, behavioural flexibility and BDNF signalling in the BTBR T+ tf/J strain, a mouse model of autism.Behav Brain Res. 2013 Aug 15;251:35-40. doi: 10.1016/j.bbr.2012.12.028. Epub 2012 Dec 25. Behav Brain Res. 2013. PMID: 23270976
-
The BTBR T+ tf/J mouse model for autism spectrum disorders-in search of biomarkers.Behav Brain Res. 2013 Aug 15;251:25-34. doi: 10.1016/j.bbr.2012.07.021. Epub 2012 Aug 9. Behav Brain Res. 2013. PMID: 22958973 Free PMC article. Review.
Cited by
-
The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models.Int J Mol Sci. 2017 Sep 7;18(9):1916. doi: 10.3390/ijms18091916. Int J Mol Sci. 2017. PMID: 28880200 Free PMC article. Review.
-
Serotonin neuron abnormalities in the BTBR mouse model of autism.Autism Res. 2017 Jan;10(1):66-77. doi: 10.1002/aur.1665. Epub 2016 Aug 1. Autism Res. 2017. PMID: 27478061 Free PMC article.
-
The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses.Psychol Med. 2023 Nov;53(15):7006-7024. doi: 10.1017/S0033291723002465. Epub 2023 Sep 6. Psychol Med. 2023. PMID: 37671673 Free PMC article. Review.
-
Would some cannabinoids ameliorate symptoms of autism?Eur Child Adolesc Psychiatry. 2012 Apr;21(4):237-8. doi: 10.1007/s00787-012-0255-z. Epub 2012 Feb 17. Eur Child Adolesc Psychiatry. 2012. PMID: 22350104 No abstract available.
-
The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex.PLoS One. 2013 Apr 24;8(4):e62189. doi: 10.1371/journal.pone.0062189. Print 2013. PLoS One. 2013. PMID: 23638000 Free PMC article.
References
-
- King BH, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc. Psychiatr. Clin. N. Am. 2006;15:161–175. - PubMed
-
- Robinson PD, Schutz CK, Macciardi F, White BN, Holden JA. Genetically determined low maternal serum dopamine b-hydroxylase levels and etiology of autism spectrum disorders. Am. J. Med. Genet. 2001;100:30–36. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous